Dr Neil Chapman clinical lead hypertension and cardiovascular disease prevention (consultant physician, honorary senior lecturer, lead)
- Patient age group
- Adults
- Consultant registered on
- 04/02/1991
- Primary medical qualifications
- MB BChir
- Gender
- Male
- Services
- Hospitals
Contact
- Phone
- 020 3313 7382
Adelle Ferguson Adom
Background
Dr Neil Chapman is a consultant in general and cardiovascular medicine and clinical pharmacology at Imperial College Healthcare NHS Trust (ICHT). He qualified from the University of Cambridge before training in general medicine, clinical pharmacology and hypertension in London and at the University of Sydney, Australia.
He specialises in the management of hypertension (high blood pressure) and cardiovascular disease prevention. He is a fellow of the British and Irish Hypertension Society (BIHS) and an accredited hypertension specialist of the European Society of Hypertension (ESH).
He is the Trust lead clinician for hypertension, and the clinical lead for the Peart-Rose clinic, a renowned tertiary referral centre for hypertension and cardiovascular risk factor management located at the Hammersmith Hospital. He is also the clinical lead for the Trust’s cardiac rehabilitation and prevention service.
His clinical and research interests include the diagnosis, investigation and management of hypertension and other cardiovascular risk factors, and both primary and secondary cardiovascular disease prevention. He works closely with local and regional partners to develop strategies to improve hypertension detection and control.
He sees outpatients with all aspects of hypertension (including confirmation and investigation of newly-diagnosed hypertension, ambulatory blood pressure monitoring, investigation and management of secondary hypertension, resistant and hard-to-control hypertension and patients who find it hard to tolerate usual treatments) and those at increased cardiovascular risk.
Expertise
Hypertension, resistant hypertension, secondary hypertension, primary cardiovascular disease prevention, secondary cardiovascular disease prevention, cardiovascular risk factor assessment and management
Research & publications
Selected major publications
1. Townsend et al, on behalf of the SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390:2160-2170
2. Chapman et al. Effect of doxazosin GITS as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118: 42-8
3. Chapman et al. Effect of Spironolactone on Blood Pressure in Subjects with Resistant Hypertension. Hypertension 2007; 49: 839-45
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35
5. Turnbull et al; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9
6. Tzourio et al, on behalf of the PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med, 2003; 163: 1069-75
7. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J, 2003; 24: 475-84
8. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.